Hepatitis C

The Lancet

Volumn 385, Issue 9973, 2015, Pages 1124-1135

  Webster, Daniel P ^a   Klenerman, Paul ^b   Dusheiko, Geoffrey M ^c  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN; ANTIVIRUS AGENT;

ACUTE HEPATITIS C; ANTIVIRAL THERAPY; CONFERENCE PAPER; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; END STAGE LIVER DISEASE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; LIMIT OF DETECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NUCLEIC ACID AMPLIFICATION; PRIORITY JOURNAL; TREATMENT DURATION; VIRUS REPLICATION; COMPLICATION; DRUG DEVELOPMENT; HEALTH CARE DELIVERY; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; TRANSMISSION;

ANTIVIRAL AGENTS; COINFECTION; DRUG DISCOVERY; HEALTH SERVICES ACCESSIBILITY; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS;

EID: 84925649961     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)62401-6     Document Type: Conference Paper

References (156)

1. E Szabó, G Lotz, C Páska, A Kiss, Z Schaff Viral hepatitis: new data on hepatitis C infection Pathol Oncol Res 9 2003 215 221
2. K Mohd Hanafiah, J Groeger, AD Flaxman, ST Wiersma Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence Hepatology 57 2013 1333 1342
3. EC Thomson, VM Fleming, J Main et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men Gut 60 2011 837 845
4. B Hajarizadeh, J Grebely, GJ Dore Epidemiology and natural history of HCV infection Nat Rev Gastroenterol Hepatol 10 2013 553 562
5. S Zaltron, A Spinetti, L Biasi, C Baiguera, F Castelli Chronic HCV infection: epidemiological and clinical relevance BMC Infect Dis 12 suppl 2 2012 S2
6. JF Perz, GL Armstrong, LA Farrington, YJ Hutin, BP Bell The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide J Hepatol 45 2006 529 538
7. G Bezemer, AR Van Gool, E Verheij-Hart the DITTO-HCV Study Group Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study BMC Gastroenterol 12 2012 11
8. MW Fried, ML Shiffman, KR Reddy et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
9. T Poynard, P Marcellin, SS Lee the International Hepatitis Interventional Therapy Group (IHIT) Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus Lancet 352 1998 1426 1432
10. MP Manns, JG McHutchison, SC Gordon et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
11. F Poordad, J McCone Jr, BR Bacon the SPRINT-2 Investigators Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
12. IM Jacobson, JG McHutchison, G Dusheiko the ADVANCE Study Team Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
13. T Asselah, P Marcellin Interferon free therapy with direct acting antivirals for HCV Liver Int 33 suppl 1 2013 93 104
14. J Halliday, P Klenerman, E Barnes Vaccination for hepatitis C virus: closing in on an evasive target Expert Rev Vaccines 10 2011 659 672
15. A Kapoor, P Simmonds, G Gerold et al. Characterization of a canine homolog of hepatitis C virus Proc Natl Acad Sci USA 108 2011 11608 11613
16. S Lyons, A Kapoor, C Sharp et al. Nonprimate hepaciviruses in domestic horses, United kingdom Emerg Infect Dis 18 2012 1976 1982
17. A Kapoor, P Simmonds, TK Scheel et al. Identification of rodent homologs of hepatitis C virus and pegiviruses MBio 4 2013 e00216 e00213
18. OG Pybus, E Barnes, R Taggart et al. Genetic history of hepatitis C virus in East Asia J Virol 83 2009 1071 1082
19. P Simmonds Genetic diversity and evolution of hepatitis C virus - 15 years on J Gen Virol 85 2004 3173 3188
20. OG Pybus, MA Charleston, S Gupta, A Rambaut, EC Holmes, PH Harvey The epidemic behavior of the hepatitis C virus Science 292 2001 2323 2325
21. RR Gray, M Salemi, P Klenerman, OG Pybus A new evolutionary model for hepatitis C virus chronic infection PLoS Pathog 8 2012 e1002656
22. T Wakita, T Pietschmann, T Kato et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome Nat Med 11 2005 791 796
23. LW Meredith, GK Wilson, NF Fletcher, JA McKeating Hepatitis C virus entry: beyond receptors Rev Med Virol 22 2012 182 193
24. A Shulla, G Randall Hepatitis C virus-host interactions, replication, and viral assembly Curr OpinVirol 2 2012 725 732
25. MT Catanese, K Uryu, M Kopp et al. Ultrastructural analysis of hepatitis C virus particles Proc Natl Acad Sci USA 110 2013 9505 9510
26. JL Kim, KA Morgenstern, C Lin et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide Cell 87 1996 343 355
27. RA Love, HE Parge, JA Wickersham et al. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site Cell 87 1996 331 342
28. CA Lesburg, MB Cable, E Ferrari, Z Hong, AF Mannarino, PC Weber Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site Nat Struct Biol 6 1999 937 943
29. P Duggal, CL Thio, GL Wojcik et al. Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts Ann Intern Med 158 2013 235 245
30. L Prokunina-Olsson, B Muchmore, W Tang et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus Nat Genet 45 2013 164 171
31. SI Khakoo, CL Thio, MP Martin et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection Science 305 2004 872 874
32. K Fitzmaurice, D Petrovic, N Ramamurthy et al. Molecular footprints reveal the impact of the protective HLA-A∗03 allele in hepatitis C virus infection Gut 60 2011 1563 1571
33. NH Shoukry, A Grakoui, M Houghton et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection J Exp Med 197 2003 1645 1655
34. E Barnes, A Folgori, S Capone et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man Sci Transl Med 4 2012 115ra1
35. A Wahid, J Dubuisson Virus-neutralizing antibodies to hepatitis C virus J Viral Hepat 20 2013 369 376
36. E Giang, M Dorner, JC Prentoe et al. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus Proc Natl Acad Sci USA 109 2012 6205 6210
37. L Kong, E Giang, T Nieusma et al. Structure of hepatitis C virus envelope glycoprotein E2 antigenic site 412 to 423 in complex with antibody AP33 J Virol 86 2012 13085 13088
38. RM Klevens, DJ Hu, R Jiles, SD Holmberg Evolving epidemiology of hepatitis C virus in the United States Clin Infect Dis 55 suppl 1 2012 S3 S9
39. S Zou, KA Dorsey, EP Notari et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing Transfusion 50 2010 1495 1504
40. M Cornberg, HA Razavi, A Alberti et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel Liver Int 31 suppl 2 2011 30 60
41. LE Thorpe, LJ Ouellet, R Hershow et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment Am J Epidemiol 155 2002 645 653
42. MR Prasad, JR Honegger Hepatitis C virus in pregnancy Am J Perinatol 30 2013 149 159
43. S Jain, N Goharkhay, G Saade, GD Hankins, GD Anderson Hepatitis C in pregnancy Am J Perinatol 24 2007 251 256
44. PG McIntyre, K Tosh, W McGuire Caesarean section versus vaginal delivery for preventing mother to infant hepatitis C virus transmission Cochrane Database Syst Rev 4 2006 CD005546.
45. NA Terrault, JL Dodge, EL Murphy et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study Hepatology 57 2013 881 889
46. M Danta, AJ Rodger Transmission of HCV in HIV-positive populations Curr Opin HIV AIDS 6 2011 451 458
47. M Danta, D Brown, S Bhagani the HIV and Acute HCV (HAAC) group Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours AIDS 21 2007 983 991
48. J Serpaggi, ML Chaix, D Batisse et al. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy AIDS 20 2006 233 240
49. T van de Laar, O Pybus, S Bruisten et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men Gastroenterology 136 2009 1609 1617
50. TC Martin Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM AIDS 27 2013 2551 2557
51. MD Hernandez, KE Sherman HIV/hepatitis C coinfection natural history and disease progression Curr Opin HIV AIDS 6 2011 478 482
52. M López-Diéguez, ML Montes, JF Pascual-Pareja the GESIDA 37/03-FIPSE 36465/03-NEAT IG5 Study Group The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients AIDS 25 2011 899 904
53. J Macías, J Berenguer, MA Japón et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus Hepatology 50 2009 1056 1063
54. CV Tovo, SC Becker, PR Almeida, B Galperim, S Chaves Progression of liver fibrosis in monoinfected patients by hepatitis C virus and coinfected by HCV and human immunodeficiency virus Arq Gastroenterol 50 2013 19 22
55. MS Sulkowski Current management of hepatitis C virus infection in patients with HIV co-infection J Infect Dis 207 suppl 1 2013 S26 S32
56. J Berenguer, J Alvarez-Pellicer, PM Martín the GESIDA3603/5607 Study Group Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus Hepatology 50 2009 407 413
57. MA Thompson, JA Aberg, P Cahn the International AIDS Society-USA Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel JAMA 304 2010 321 333
58. CM Wyatt, C Malvestutto, SG Coca, PE Klotman, CR Parikh The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis AIDS 22 2008 1799 1807
59. CH Hinkin, SA Castellon, AJ Levine, TR Barclay, EJ Singer Neurocognition in individuals co-infected with HIV and hepatitis C J Addict Dis 27 2008 11 17
60. R Bedimo, AO Westfall, M Mugavero, H Drechsler, N Khanna, M Saag Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients HIV Med 11 2010 462 468
61. F Collin, X Duval, V Le Moing the ANRS CO8 APROCO-COPILOTE study group Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults AIDS 23 2009 1021 1024
62. EA Operskalski, A Kovacs HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies Curr HIV/AIDS Rep 8 2011 12 22
63. RA de Almeida Ponde Enzyme-linked immunosorbent/chemiluminescence assays, recombinant immunoblot assays and nucleic acid tests in the diagnosis of HCV infection Eur J Clin Microbiol Infect Dis 32 2013 985 988
64. P Klenerman, A Kim HCV-HIV coinfection: simple messages from a complex disease PLoS Med 4 2007 e240
65. AP Avó, I Agua-Doce, A Andrade, E Pádua Hepatitis C virus subtyping based on sequencing of the C/E1 and NS5B genomic regions in comparison to a commercially available line probe assay J Med Virol 85 2013 815 822
66. EM Batty, TH Wong, A Trebes et al. A modified RNA-Seq approach for whole genome sequencing of RNA viruses from faecal and blood samples PLoS One 8 2013 e66129
67. V Gonzalez, M Gomes-Fernandes, E Bascunana et al. Accuracy of a commercially available assay for HCV genotyping and subtyping in the clinical practice J Clin Virol 58 2013 249 253
68. B Cobb, PJ Pockros, RA Vilchez, JM Vierling HCV RNA viral load assessments in the era of direct-acting antivirals Am J Gastroenterol 108 2013 471 475
69. EC Thomson, JA Smith, P Klenerman The natural history of early hepatitis C virus evolution; lessons from a global outbreak in human immunodeficiency virus-1-infected individuals J Gen Virol 92 2011 2227 2236
70. V Racanelli, B Rehermann Hepatitis C virus infection: when silence is deception Trends Immunol 24 2003 456 464
71. R Loomba, MM Rivera, R McBurney et al. The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes Aliment Pharmacol Ther 33 2011 559 565
72. S Beinhardt, BA Payer, C Datz et al. A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection J Hepatol 59 2013 972 977
73. European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference AIDS 25 2011 399 409
74. K Deterding, N Grüner, P Buggisch the Hep-Net Acute HCV-III Study Group Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial Lancet Infect Dis 13 2013 497 506
75. DP Webster, T Wojcikiewicz, M Keller et al. Spontaneous clearance and treatment of acute hepatitis C infection in HIV-positive men with 48 weeks of interferon-alpha and ribavirin Int J STD AIDS 24 2013 179 183
76. YC Gilleece, RE Browne, D Asboe et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin J Acquir Immune Defic Syndr 40 2005 41 46
77. JT Gerlach, HM Diepolder, R Zachoval et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance Gastroenterology 125 2003 80 88
78. J Wiegand, P Buggisch, W Boecher the German HEP-NET Acute HCV Study Group Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study Hepatology 43 2006 250 256
79. P Bedossa, T Poynard the The METAVIR Cooperative Study Group An algorithm for the grading of activity in chronic hepatitis C Hepatology 24 1996 289 293
80. T Poynard, P Bedossa, P Opolon for the OBSVIRC METAVIR CLINIVIR DOSVIRC groups Natural history of liver fibrosis progression in patients with chronic hepatitis C Lancet 349 1997 825 832
81. HH Thein, Q Yi, GJ Dore, MD Krahn Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression Hepatology 48 2008 418 431
82. HH Thein, Q Yi, GJ Dore, MD Krahn Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis AIDS 22 2008 1979 1991
83. L Castéra, B Le Bail, F Roudot-Thoraval et al. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores J Hepatol 50 2009 59 68
84. AJ van der Meer, BJ Veldt, JJ Feld et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis JAMA 308 2012 2584 2593
85. S Bruno, T Stroffolini, M Colombo the Italian Association of the Study of the Liver Disease (AISF) Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study Hepatology 45 2007 579 587
86. S Zeuzem, P Andreone, S Pol the REALIZE Study Team Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
87. C Hezode, H Fontaine, C Dorival et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis Gastroenterology 147 2014 132 142 e4.
88. D Ge, J Fellay, AJ Thompson et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
89. JJ Kiser, JR Burton Jr, GT Everson Drug-drug interactions during antiviral therapy for chronic hepatitis C Nat Rev Gastroenterol Hepatol 10 2013 596 606
90. S Chevaliez Antiviral activity of the new DAAs for the treatment of hepatitis C virus infection: virology and resistance Clin Res Hepatol Gastroenterol 35 suppl 2 2011 S46 S51
91. IM Jacobson, P Marcellin, S Zeuzem et al. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin Hepatology 56 2012 567 575
92. JM Pawlotsky Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus Hepatology 53 2011 1742 1751
93. IM Jacobson, JM Pawlotsky, NH Afdhal et al. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C J Viral Hepat 19 suppl 2 2012 1 26
94. MW Fried, M Buti, GJ Dore et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study Hepatology 58 2013 1918 1929
95. MS Sulkowski, T Asselah, J Lalezari et al. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial Hepatology 57 2013 2143 2154
96. S Pol, RH Ghalib, VK Rustgi et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial Lancet Infect Dis 12 2012 671 677
97. KV Kowdley, E Lawitz, I Crespo et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial Lancet 381 2013 2100 2107
98. IM Jacobson, GJ Dore, GR Foster et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial Lancet 384 2014 403 413
99. M Manns, P Marcellin, F Poordad et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial Lancet 384 2014 414 426
100. X Forns, E Lawitz, S Zeuzem et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial Gastroenterology 146 2014 1669 1679 e3.
101. E Lawitz, EJ Gane Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 369 2013 678 679
102. MP Manns, JM Vierling, BR Bacon et al. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis Gastroenterology 147 2014 366 376 e6.
103. E Lawitz, FF Poordad, PS Pang et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial Lancet 383 2014 515 523
104. MS Sulkowski, DF Gardiner, M Rodriguez-Torres the AI444040 Study Group Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N Engl J Med 370 2014 211 221
105. MS Sulkowski, DF Gardiner, M Rodriguez-Torres et al. Sustained virologic response with daclatasvir plus sofosbuvir ± ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC) J Hepatol 58 suppl 1 2013 S570
106. N Afdhal, KR Reddy, DR Nelson the ION-2 Investigators Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection N Engl J Med 370 2014 1483 1493
107. KV Kowdley, SC Gordon, KR Reddy the ION-3 Investigators Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis N Engl J Med 370 2014 1879 1888
108. FE Membreno, EJ Lawitz The HCV NS5B nucleoside and non-nucleoside inhibitors Clin Liver Dis 15 2011 611 626
109. M Bourliere, JP Bronowicki, V De Ledinghen Ledipasvir/sofosbuvir fixed dose combination is safe and efficacious in cirrhotic patients who have previously failed protease inhibitor based triple therapy Hepatology 60 suppl 2014 LB6
110. Kohli A, Sims Z, Marti M, et al. Combination oral, ribavirin free, antiviral therapy to optimise treatment outcomes for hepatitis C GT-1 treatment naïve patients: interim results from the NIAID SYNERGY trial. 64th Annual Meeting of the American Association for the Study of Liver Diseases; Washington, DC, USA; Nov 1-5, 2013. Abstract LB-2.
111. G Everson, T Tran, W Towner et al. Safety and efficacy of treatment with the interferon-free combination of sofosbuvir + GS-5816 for 12 weeks in treatment naïve patients with genotype 1-6 HCV infection J Hepatol 60 suppl 2014 Abstract O111.
112. JJ Feld, KV Kowdley, E Coakley et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin N Engl J Med 370 2014 1594 1603
113. S Zeuzem, IM Jacobson, T Baykal et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin N Engl J Med 370 2014 1604 1614
114. F Poordad, C Hezode, R Trinh et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis N Engl J Med 370 2014 1973 1982
115. P Ferenci, D Bernstein, J Lalezari the PEARL-III Study the PEARL-IV Study ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV N Engl J Med 370 2014 1983 1992
116. P Andreone, MG Colombo, JV Enejosa et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection Gastroenterology 147 2014 359 365 e1.
117. E Lawitz, MS Sulkowski, R Ghalib et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study Lancet 384 2014 1756 1765
118. D Jensen, J O'Leary, P Pockros Safety and efficacy of sofosbuvir containing regimens for hepatitis C: a real world experience in a diverse longitudinal observational cohort Hepatology 60 suppl 2014 219A
119. D Dietrich, B Bacon, S Flamm Sofosbuvir and simeprevir based regimens in the TRIO network: academic and community treatment of a real world heterogenous population Hepatology 60 suppl 2014 220A
120. M Manns, S Pol, IM Jacobson the HALLMARK-DUAL Study Team All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study Lancet 384 2014 1597 1605
121. S Pianko, S Flamm, M Shiffman et al. High efficacy of treatment with sofosbuvir+GS-5816 ± ribavirin for 12 weeks in treatment experienced patients with genotype 1 or 3 HCV infection Hepatology 60 suppl 2014 297A
122. E Lawitz, E Gane, B Pearlman et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial Lancet 2014 published online Nov 11. http://dx.doi.org/10.1016/S0140-6736(14)61795-5
123. Everson GT, Sims KD, Thuluvath PJ, et al. Phase 2b study of the interferon-free and ribavirin-free combination of daclatasvir, asunaprevir, and BMS-791325 for 12 weeks in treatment-naïve patients with chronic HCV genotype 1 infection. 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); Washington, DC, USA; Nov 1-5, 2013: abstr LB1.
124. A Muir, F Poordad, J Lalezari All oral fixed dose combination with daclatasvir asunaprevir and BMS 791325 plus or minus ribavirin for patients with chronic hepatitis C genotype 1 infection and compensated cirrhosis: Unity -2 phase 3 SVR12 results Hepatoloogy 60 suppl 2014 LB 12
125. Z Plaza, V Soriano, E Vispo et al. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor Antivir Ther 17 2012 921 926
126. N Antaki, A Craxi, S Kamal et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report Liver Int 30 2010 342 355
127. GJ Dore, E Lawitz, C Hezode et al. Daclatasvir combined with peginterferon alfa-2A and ribavirin for 12 or 16 weeks in patients with HCV genotype 2 or 3 infection: COMMAND GT2/3 STUDY J Hepatol 58 suppl 1 2013 S570 S571
128. F McPhee, N Zhou, J Ueland et al. Pre-existence, emergence and persistence of HCV genotype 4 NS5A resistance variants from the phase 2B COMMAND-1 study: Daclatasvir plus peginterferon-alfa/ribavirin in treatment-naive patients J Hepatol 58 suppl 1 2013 S492
129. C Moreno, C Hezode, P Marcellin et al. Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4 J Hepatol 2015 10.1016/j.jhep.2014.12.031 published online Jan 14.
130. Lawitz E, Poordad F, Brainard DM, et al. Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study. 64th Annual Meeting of the American Association for the Study of Liver Diseases; Washington, DC, USA; Nov 1-5, 2013: abstr LB-4.
131. IM Jacobson, SC Gordon, KV Kowdley the POSITRON Study the FUSION Study Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options N Engl J Med 368 2013 1867 1877
132. S Zeuzem, GM Dusheiko, R Salupere the VALENCE Investigators Sofosbuvir and ribavirin in HCV genotypes 2 and 3 N Engl J Med 370 2014 1993 2001
133. Nelson DR. All oral 12 week combination treatment with daclatasvir and sofosbuvir in patients infected with HCV genotype 3: ALLY-3 phase 3 study. 65th Annual Meeting of the American Association for the Study of Liver Diseases; Boston, MA, USA; Nov 7-11, 2014: abstr LB3.
134. E Gane, RH Hyland, D An et al. Sofosbuvir/ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients, and genotype-1 patients with prior sofosbuvir treatment experience J Hepatol 60 suppl 2014 S3 S4
135. Ruane PJ, Ain D, Riad J, et al. Sofosbuvir plus ribavirin in the treatment of chronic HCV genotype 4 infection in patients of Egyptian ancestry. 64th Annual Meeting of the American Association for the Study of Liver Diseases; Washington, DC, USA. Nov 1-5, 2013: abstr 1090.
136. Hezode C et al. RESULTS Results from the phase 2 PEARL-I study: interferon-free regimens of ABT-450/r + ABT-267 with or without ribavirin in patients with HCV genotype 4 infection. 49th annual meeting of the European Association for the Study of the Liver; London, UK; April 9-13, 2014: abstr O58.
137. Hassanein T, Sims KD, Bennett M, et al. All-oral therapy with daclatasvir in combination with asunaprevir and BMS-791325 for treatment-naive patients with chronic HCV genotype 4 infection. 49th annual meeting of the European Association for the Study of the Liver; London, UK; April 9-13, 2014: abstr 1163.
138. JK Rockstroh, S Bhagani Managing HIV/hepatitis C co-infection in the era of direct acting antivirals BMC Med 11 2013 234
139. K Lacombe, N Valin, H Stitou et al. Efficacy and tolerance of telaprevir in HIV-hepatitis C virus genotype 1-coinfected patients failing previous antihepatitis C virus therapy: 24-week results AIDS 27 2013 1356 1359
140. MS Sulkowski, KE Sherman, DT Dieterich et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial Ann Intern Med 159 2013 86 96
141. CA Chastain, S Naggie Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014 Curr HIV/AIDS Rep 10 2013 408 419
142. DS Fierer, DT Dieterich, MP Mullen et al. Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men Clin Infect Dis 58 2013 873 879
143. Osinusi A, Townsend K, Nelson A, et al. Use of Sofosbuvir/ledipasvir fixed dose combination for treatment of HCV genotype-1 infection in patients coinfected with HIV (interim results). 49th annual meeting of the European Association for the Study of the Liver; London, UK; April 9-13, 2014: abstr O14.
144. M Sulkowski, C Hezode, J Gerstoft et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial Lancet 2015 published online Nov 11. http://dx.doi.org/10.1016/S0140-6736(14)61793-1
145. MS Sulkowski, S Naggie, J Lalezari the PHOTON-1 Investigators Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection JAMA 312 2014 353 361
146. Sulkowski MS, Rodriguez-Torres M, Lalezari JP, et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). 64th Annual Meeting of the American Association for the Study of Liver Diseases. Washington, DC, USA; Nov 1-5, 2013: abstr 212.
147. Curry MP, Forns X, Chung RT, et al. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. 64th Annual Meeting of the American Association for the Study of Liver Diseases. Washington, DC, USA; Nov 1-5, 2013: abstr 213.
148. S Flamm, G Everson, M Charlton et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study Hepatology 60 suppl 2014 320A
149. A Coilly, B Roche, J Dumortier et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience J Hepatol 60 2014 78 86
150. M Charlton Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents - a potentially lethal cocktail Hepatology 54 2011 3 5
151. M Charlton, E Gane, MP Manns et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation Gastroenterology 148 2014 108 117
152. R Reddy, G Everson, S Flamm et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective, multicenter study Hepatology 60 suppl 2014 49A
153. Brown R, Reddy KR, O'Leary J. Safety and efficacy of new DAA therapy for hepatitis C post transplant: interval results from the HCV TARGET longitudinal observational study. Annual Meeting of the American Association for the Study of Liver Diseases; Boston, USA; Nov 7-12, 2014: abstr LB-4.
154. PY Kwo, PS Mantry, E Coakley et al. An interferon-free antiviral regimen for HCV after liver transplantation N Engl J Med 371 2014 2375 2382
155. T Garimella Evaluation of drug-drug interaction between daclatasvir and methadone or buprenorphine/naloxone J Int AIDS Soc 17 suppl 3 2014 19628
156. R van Heeswijk Pharmacokinetic interaction between telaprevir and methadone Antimicrob Agents Chemother 57 2013 2304 2349